Buyers can request confirmation of recoverable cost categories in advance, to which the Regulator must respond promptly ...

Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic ...

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b Rew ...

Over the past decade, several tumor-based predictors of cetuximab efficacy have been identified, yet most function as ...

Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss ...